John Pullman, MD
Internal Medicine · Butte, MTNPI 1518998426
Payments from drug & device makers
Across 1,764 payments — averaging $3380.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3M
- Novo Nordisk AS$828K
- Pfizer$503K
- Boehringer Ingelheim$270K
- Eli Lilly$266K
- Janssen Research & Development, LLC$210K
- plus $896K from 41 others
Across 26 payments — averaging $618.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$12K
- AbbVie$2K
- Regeneron$1K
- Novo Nordisk AS$690
What the payments were for
- Speaking & faculty fees$5633%
- Travel & lodging$9,71852%
- Food & beverage$8,39045%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,962,705 in reported general payments places this provider in the 95th percentile of 244 internal medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 171 | $196,291 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 43 | $172,321 |
| EliquisApixaban | 97 | $82,275 |
| MounjaroTirzepatide | 42 | $48,053 |
| JardianceEmpagliflozin | 40 | $41,405 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 121 | $37,933 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $35,285 |
| JanuviaSitagliptin Phosphate | 40 | $35,221 |
| XareltoRivaroxaban | 50 | $34,218 |
| FarxigaDapagliflozin Propanediol | 33 | $29,300 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $28,903 |
| MyrbetriqMirabegron | 36 | $20,951 |
| TrulicityDulaglutide | 19 | $18,845 |
| TradjentaLinagliptin | 11 | $15,362 |
| Repatha SureclickEvolocumab | 19 | $15,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $555 | $196,291171 claims |
| PfizerEliquis, Abrysvo, Premarin | $503,422 | $122,671230 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $490 | $68,99275 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $270,107 | $64,51366 claims |
| MerckJanuvia | $29,906 | $35,22140 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arnuity Ellipta | $19,532 | $34,35888 claims |
| Johnson & JohnsonXarelto | $152,999 | $34,21850 claims |
| AstraZenecaFarxiga | $2,990,654 | $29,30033 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $20,95136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 244 internal medicine providers in Montana.
Other internal medicine in Butte
- David ChamberlainButte$8K
- Joe GregoryButte$1K
- Paul SiddowayButte$374
- Florian CorteseButte$355
- Clancy ConeMissoula$2.5M
- Scott WollerFt. Harrison$768K
- Joseph PeilaBillings$148K
- Justen RudolphBillings$99K
- Hayley MillerMissoula$97K
- Ethan PauleyBillings$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.